Pharmaceutical care for a patient with parapsilosis Candidaemia treated with high dose Fluconazole
ZHONG Ling1 LOU Yan2 LI Ben1
1.Department of Pharmacy, the Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510120, China; 2.Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangdong Province, Guangzhou 510515, China
Abstract：Fluconazole, a three azole antifungal agent, is widely used in the treatment of Candida and Cryptococcal infections. However, with the increasingly prominent problem of Candida resistance, the choice of antifungal drugs and the use of dose has become a difficult point in clinical medication. This paper makes analysis for a case with parapsilosis Candidaemia treated with high dose Fluconazole, from the angle of disease diagnosis, treatment and the safety of high dose Fluconazole, combined with pharmaceutical car, and evaluates and intervenes the safety and rationality of drug use. The article provides reference for clinical rationly application of Fluconazole in the treatment of parapsilosis Candidaemia.
钟玲1 娄艳2 黎奔1. 高剂量氟康唑治疗近平滑念珠菌感染的药学监护1例分析[J]. 中国医药导报, 2018, 15(10): 127-130.
ZHONG Ling1 LOU Yan2 LI Ben1. Pharmaceutical care for a patient with parapsilosis Candidaemia treated with high dose Fluconazole. 中国医药导报, 2018, 15(10): 127-130.
[1] 中华医学会“念珠菌病诊治策略高峰论坛”专家组.念珠菌病诊断与治疗：专家共识[J].中国感染与化疗杂志，2011，11（2）：81-95.
[2] 蒋玉兰，薛小萍.PCT和CRP联合检测对血液病患者真菌感染的诊断价值[J].国际检验医学杂志，2014，35（19）：2685-2686.
[3] 马晓薇，罗永艾.降钙素原在侵袭性真菌感染诊断中的应用价值研究[J].中华医院感染学杂志，2012，22（5）：904-906.
[4] Pappas PG，Kauffman CA，Andes D，et al. Clinical practice guidelines for the management of candidiasis：2009 update by the Infectious Diseases Society of America [J]. Clin Infect Dis，2009，48（5）：503-535.
[5] Cornely OA，Bassetti M，Calandra T，et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012：non-neutropenic adult patients [J]. Clin Microbiol Infect，2012，18（7）：19-37.
[6] Alp S ，Arikan-akdaqi S，Gulmez S，et al. Epidemiology of Candidaemia in a tertiary care university hospital：10-years with 381 Candidaemia episodes between 2001 and 2010 [J]. Mycoses，2015，58（8）：498-505.
[7] Kibbler CC，Seaton S，Barnes RA，et al. Management and outcome of bloodstream Infections due to Candida species in England and Wales [J]. J Hosp Infect，2003，54（l）：18-24.
[8] Almirante B，Rodriguez D，Cuenca-Estrella M，et al. Epidemiology，risk factors，And Prognosis of Candida parapsilosis bloodstream infections：case-control population-based surveillance study of patients in Barcelona，Spain，from 2002 to 2003 [J]. J Clin Microbiol，2006，44（5）：1681-1688.
[9] 丁秀荣，苏建荣.氟康唑对近平滑念珠菌生物膜的影响[J].首都大学医学报，2014，35（4）433-437.
[10] Kovaeieova G，KruPova Y，Lovaszova M，et al. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer Patient Population：Is there a Correlation between in-vitro resistance to fluconazole and the outcome of fungemia [J]. Infect Chemother，2000，6（4）： 216-221.
[11] Sarvikivi E，Lyytikainen O，Soll DR，et al. Emergence of Fluconazole resistance in a Candida Parapsilosis strain that caused infections in a Neonatal intensive care unit [J]. J Clin Microbiol，2005，43（6）：2729-2735.
[12] Pfaller MA，DJDiekema. Twelve years of fluconazole in clinical Practice： global Trends in species distribution and fluconazole susceptibility of bloodstream isolates Of Candida[J]. Clin Microbiol Infect，2004，10：11-23.
[13] 桑福德，等.热病[M].北京：中国协和医科大学出版社，2014：114.
[14] Clancy CJ，Yu VL，Morris AJ，et al. Fluconazole MIC and the Fluconazole Dose/MIC ratio correlate with therapeutic response among patients with Candidemia [J]. Antimicrob Agents Chemother，2005，49（8）：3171-3177.
[15] Torres HA, Kontoyiannis DP, Rolston KV. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia： an observational，noncomparative retrospective study [J]. Support Care Cancer，2004，12（7）：511-516.
[16] Schuster MG，Edwards JE Jr，Sobel JD，et al. Empirical Fluconazole versus Placebo for Intensive Care Unit Patients[J]. Ann Intern Med，2008，149（2）：83-90.
[17] Duswald KH，Penk A，Pittrow L. High-dose therapy with fluconazole ≥800 mg/day [J]. Mycoses，1997，40（7-8）：267-277.
[18] 庄启州.氟康唑不良反应文献分析[J].医药导报，2011， 30（11）：1530-1532.
[19] 郑重践，林妙娴.1例房颤合并真菌感染患者室性心动过速诱因分析[J].中国药物评价，2014，31（5）：300-301
[20] 张凤香，司忠义，李树青，等.氟康唑致尖端扭转型室速1例[J].国际心血管病杂志，2006，33（5）：286.
2018, Vol. 15 
京公网安备 11010502046598号